HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.
Bhupendra Gopalbhai Prajapati, Speaker at Pharmaceutical Conference
Ganpat University, India
Title : Role of nanoformulations in treating Cystic Fibrosis


Cystic fibrosis is a genetic disease caused by CFTR gene mutations resulting in impaired mucociliary clearance and causing infection, inflammation, and insufficiently working respiratory system. This disease affects more than seventy thousand people across the globe. Multi-organ dysfunction is associated with the aberrant transport of electrolytes across the epithelium. The lung diseases related to cystic fibrosis form a significant part of mortality and morbidity because of this disease. The mutation in the CFTR gene causes impaired chloride ion secretion leading to sticky and thick mucus secretion, which provides for complications in the airway causing chronic lung infection and inflammatory reactions. Bacterial infections are very prevalent in this disease and cause life-threatening circumstances. Standard treatment involves using antibiotics, which have been proven ineffective because the amount of drug that reaches the site of action has always been insufficient. This disease has enormous potential for genetic mutation, which renders it a limited option for cure. We have focused on providing a valid alternative to the conventional therapies available in the form of nanoformulations targeting the root cause of the disease. The applications of nanotechnology in the CF specified field have been highlighted with the help of illustrating the natural and synthetic polymers and various strategies to overcome physiological barriers.

Audience Take Away Notes:

  • Current trends and updates on nanoformulation for cystic fibrosis
  • Apply the knowledge in the development of formulation and optimization
  • Gain knowledge of Novel formulation approaches and targeting can be extended in their research and job
  • Yes, it can be.
  • Yes it can provide a practical solution


Dr. Bhupendra Prajapati is a Professor in the Department of Pharmaceutics, Shree S.K.Patel College of Pharmaceutical Education and Research, Ganpat University, Gujarat, India. He has more than 20 years of academic and research experience, and has published more than 100 research and review papers in international and national Journals. Under his editorial two books are under process and he authored 20 book chapters in the field of novel drug delivery. He published two Indian patent and three applications under evaluation. He is a reviewer in three high-impact journals and is on the editorial board of several scientific journals.